Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Mind & Matter

Mind & Matter artwork

Blocking a Brain Fat Carrier May Ease Anxiety Without Addiction | Steven Laviolette | 234

Jun 16, 20251 hr 13 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail How dietary fats and cannabinoids shape brain function and mental well-being. Episode Summary: Dr. Steven Laviolette discusses the role of lipids, particularly endocannabinoids and fatty acids, in brain signaling and mental health, discussing how dietary omega-3 and omega-6 imbalances, prenatal THC exposure, and fatty acid binding proteins (FABPs) impact mood, anxiety, and neuroinflammation, while highlighting potential dietary interventions to mitigate these effects. About the guest: Steven Laviolette, PhD is a professor at the University of Western Ontario, holding a PhD, and his lab focuses on the brain’s cannabinoid system and its role in mental health. He investigates how cannabinoids and fatty acids influence brain development and disorders like anxiety and schizophrenia. Discussion Points: The brain uses fats like endocannabinoids (e.g., anandamide, 2-AG) not just for structure but as signaling molecules to regulate emotional and cognitive processing. Prenatal THC exposure in rodents skews the omega-3/omega-6 balance toward pro-inflammatory omega-6, leading to cognitive and mood issues in offspring, but omega-3 supplementation can mitigate these effects. Fatty acid binding proteins (FABPs), especially FABP5, shuttle endocannabinoids like anandamide to degradation sites, and inhibiting FABP5 increases anandamide levels, reducing anxiety and depression without addictive side effects. FABP5 inhibitors show promise as safer alternatives to benzodiazepines. Both THC and CBD can induce problems during early development, challenging the notion that CBD is universally safe, especially during pregnancy. Dietary interventions, like omega-3 supplementation or antioxidants (e.g., L-theanine, N-acetylcysteine), may counteract the negative psychiatric effects of cannabinoid exposure, particularly during adolescence. The North American diet, high in omega-6, contributes to neuroinflammation and mental health issues, underscoring the need for nutritional neuroscience to address these imbalances. Related episode: M&M 165: PUFAs in Brain Health & Disease, Dietary Fats, Brain Lipids, Nutrition | Richard Bazinet *Not medical advice. Support the show Support my work: Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly. Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health. For all the ways you can support my efforts.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Nick JikomesWhether food, drugs or ideas, what you consume, influences, who you become. On the mind and matter podcast, we learn together from the best scientists and thinkers alive today about how your mind body reacts to what you feed it before starting mind and matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience, where I focused on neuro endocrinology and the neurobiology of behavior, and before that, I specialized in molecular developmental and evolutionary genetics. I use my scientific background to help parse and translate the information that guests share on the podcast. In addition to the podcast, I write long form written content inspired by the show, where I integrate what I've learned across episodes. I also have a free weekly newsletter where I provide you with upcoming guests, share links and provide commentary on scientific studies and research that I'm reading and more visit mind and matter.substack.com. To find all of my content you thank you for joining me again on the podcast for the second time. Thanks for having me Nick. You want to just start off by reminding everyone who you are and what your lab studies

Steven LavioletteSure. My name is Steve Laviolette. I'm a professor at the University of Western Ontario, my lab is primarily interested in the cannabinoid system in the brain and how it relates to mental health. We're looking at various different models, including the impacts of exposure to cannabinoids during sensitive periods of brain development, like prenatal development, adolescent brain development. And we're also looking at modulatory systems of the cannabinoid system, including systems like the fatty acid binding protein system as an example.

Nick JikomesAnd so I want to give everyone a sense for how lipids fats are used in the brain. As some listeners will know, but many may not know, the endocannabinoids themselves are an example of how fats are used in the brain for signaling, rather than just structural purposes. But when we think about endogenous cannabinoids, when we think about some of the lipid signaling molecules and related things we'll talk about, can you just give people a sense for how the brain uses fats beyond just structural components of membranes and things like that? Right?

Steven LavioletteNo, it's an important question that's often overlooked because I think we tend to focus more on focus more on the neurochemicals and the neurotransmitters, and sort of ignore the bigger picture. Fatty acids are really the major I mean, the brain is mostly fat. It's mostly fat, obviously, including myelination and a lot of fatty acids signaling molecules and whatnot. And beyond, of course, the structural importance of fatty acids which make up, you know, most of the brain, the cellular membranes and whatnot. There's a lot of fatty acids signaling molecules in the brain as well. And of course, when they have to traverse through an aqueous substrate, like like the intracellular milieu, for example, we need to have specialized proteins that can sort of chaperone those hydrophobic molecules across these aqueous membranes. So that's why we have a lot of different fatty acid signaling systems in the brain, including the endocannabinoid system, that relies on these specialized proteins that allow the signals, the signals to get through to where they need to go in the brain.

Nick JikomesYeah. So, you know, everyone knows sort of oil and water don't mix well together. Fats and aqueous things, watery things don't mix well together on their own. And that's why, I guess you know another way to get into this and think about it is the same reason you sort of have these chaperone lipoproteins in your blood that shuttle cholesterols and fats around. We've also got various things in the brain that help us shuttle lipids around. And one of the reasons we do that, that the nervous system has to do that, is because these fats aren't just components of membranes. They are signaling molecules that actually help the brain process and transfer information

Steven Laviolettearound absolutely and of course, they also serve as important precursors for a lot of different neurotransmitters. So they're involved in the biosynthetic pathways of a wide variety of neurotransmitters, including the naturally occurring cannabinoids in the brain.

Nick JikomesAnd so what exactly are can you just give everyone a crash course in what the cannabinoids are at the molecular level and where they ultimately come from,

Steven Lavioletteright? So, so the endocannabinoids are, you know, they're one of the, the most evolutionarily oldest systems in the vertebrate brain, and they're seen, you know, across the entire revolutionary spectrum. And. What they primarily do is regulate signaling in the brain. So they're primarily sort of retrograde modulators of neurotransmission. So for example, the brain has to maintain a balance between excitation and inhibition. So the endocannabinoid system is very importantly involved in regulating inhibitory processes in the brain. So the presynaptic neuron will release endocannabinoids. And the two major endocannabinoids are called two arachidonoglycerol, or two Ag, and then anandamide is the other major one. So those are the two major sort of naturally occurring endocannabinoids. They serve slightly different functions. We're still trying to figure out exactly what they do, but we know that both of them are involved in sort of this retrograde inhibitory modulation of the of the synapse itself, and primarily involved in sort of regulating excitation and inhibition balance in various brain areas. And of course, they're they're highly regulated in areas of the brain that are responsible for emotional processing, for cognitive processing, like the frontal cortex, the amygdala, for example, the striatum. So you can imagine that disturbances and the balances between those endocannabinoids are major risk factors for a lot of different mental health

Nick Jikomesdisorders. Yeah, I guess bird's eye view. You know, the brain, you know, there's information flowing through the brain in the form of, you know, electrochemical activity. That information needs to be patterned. It needs to be structured and constrained. And in simplified terms, you don't want over excitation, you don't want under excitation. And the cannabinoids are an important mechanism preventing things from getting out of hand or underhand, exactly, yeah. And so, like, where, where? How does our body make them? Like, what are the what are the pieces that go into producing them, and where do they ultimately come from?

Steven LavioletteWell, two of the major precursors for the endocannabinoids are DHA and EPA. I won't, I won't attempt to pronounce the full name. But those are, of course, the omega three fatty acids. And the omega three fatty acids primarily come from the diet. So you know, you're, I'm sure you're aware that there's a lot of people are deficient in omega three fatty acids. They don't get enough in their diets. And of course, we, we rely on those omega threes to sort of serve as the pre EPA and DHA to serve as the precursor molecules for some of these naturally occurring endocannabinoids. So it's a very complex biosynthetic chain, but ultimately, we do need to have those, those sort of, those dietary precursors to get the adequate production of the of the endocannabinoids,

Nick JikomesI see. So it's the Omega three is not the Omega sixes that that ultimately are the precursors to endocannabinoids. The

Steven LavioletteOmega six is also are involved in some of that pathway as well, but it's primarily believed to be the Omega threes that are sort of the major especially DHA and EPA, which which serve as the major precursors I

Nick Jikomessee. And so when these things are used in the brain. So endogenous cannabinoids are famously made on demand. So as opposed to a lot of other chemical messengers in the brain, like neurotransmitters, they tend not to be packaged and sitting around waiting to be used, they tend to be made on demand. So are they basically just kind of clipped off of fatty components of the membrane,

Steven Laviolettepretty much? Yeah. I mean, it's a complex pathway, but they're, you know, they're primarily, you're right. They're sort of synthesized on demand, particularly when we're talking about mechanisms I was just referring to, like the necessity for retrograde inhibitory signaling across synapses and that sort of thing.

Nick JikomesAnd so what you know, other than being retrograde messengers, what can you tell us about endocannabinoids that will sort of set us up to understand things like anxiety disorders and some of the other things we're going to get into in this conversation? Great. So

Steven Lavioletteyou know both both the naturally occurring endocannabinoids to ag and anandamide, are critically involved in regulating emotional states, you know, reward processing, averse of the aversive states as well. And, of course, anxiety levels. So we know that levels of anandamide, for example, which, and I primarily will focus on that, because that's sort of been the focus of our work. And and my primarily, anandamide is, is, very importantly, involved in emotional regulation, if you have too little anandamide that's linked to increased anxiety. But if you can somehow increase the levels of naturally occurring anandamide that's been linked to decreased levels of anxiety as well. So there's there's a strong sort of balance between the levels of these naturally occurring endocannabinoids and sort of your baseline emotional state, your sort of state of anxiety. And that's been shown in both clinical and pre clinical research as well.

Nick JikomesAnd one thing I want to connect here up front is, what can you tell us about the potential connections that. Cannabinoid system may be involved in between things like anxiety and mood disorders on the one hand, and things like neuro inflammation on the other. Is there a deep connection there between inflammation and mood regulation?

Steven LavioletteThere is, I mean, that it's, it's an emerging field, I think, trying to understand how neuroinflammation is involved in regulating mood and anxiety. We know that neuron inflammation can be strongly regulated by omega three fatty acids, for example. So for example, the omega three fatty acids are known to decrease neuron inflammation. Omega six is our more pro inflammatory. So that's another component of what we study in the lab is looking at the balance between omega three and Omega six and how that controls neuro inflammation, and we've been able to show that that regulatory balance is also critical for sort of baseline levels of anxiety, not just anxiety mood, but also cognitive, cognitive behaviors as well. So, you know, there is certainly a functional link between anandamide and neuro inflammatory, inflammatory mechanisms, but they go through a wide array of different signaling pathways. So for example, they're, you know, they're linked to the PPAR system, which is the peroxis, peroxisome proliferator activation receptors. They're linked to nuclear transcription of various intracellular components that are involved in the inflammatory state of the cell, and, yeah, but sort of, you know, broad perspective is that they're definitely involved in regulating neuro inflammatory mechanisms and disturbances in those in those neuroinflammatory processes have definitely been linked to mood and anxiety disorders. So the

Nick JikomesOmega threes and the Omega six is these are long chain polyunsaturated fatty acids, which, for people that don't think about lipids a lot, they're long molecules. They're usually bendy because they've got multiple double bonds. So they've got, you know, particular structures to them that give them the functions they have. And you know, as you've written in this review paper I looked at before meeting you today, and as I've discussed in other contexts on the podcast, one thing that seems to be important about the Omega three and six fatty acids is that they're similar to each other, but they're functionally divergent. In fact, they often kind of do opposing things, and you can't convert one into the other. And so this brings us to the concept of basically dietary balance, that that these things are supposed to be in relatively comparable balance, because they often have, say, pro inflammatory effects on the one hand versus anti inflammatory, or resolving effects on the other. What can you say about that in terms of sort of dietary PUFA intake and this concept of the balance between the Omega threes and the Omega sixes,

Steven Lavioletteright? Well, I'll frame that in some of our some of our other research. So we've been looking at primarily the impact of prenatal THC exposure. So we published a couple of papers recently looking at how THC exposure, which is obviously an extrinsic cannabinoid, but that can strongly throw off the balance of the Omega threes and Omega six. So in a recent paper that we published in molecular psychiatry, we found that exposure to THC during pregnancy, using an animal model, it throws off the balance of omega six and Omega three in the brain. And so we did imaging of those pathways in the brain, and showed that when that balance was thrown off, regardless of and again, they sort of have to be, you want to have sort of an ideal ratio between omega six and Omega three. When that balance gets thrown off the the offspring of those animals that have been exposed to THC, they have problems with cognitive, cognition. They have problems with mood and anxiety symptoms that persisted all the way into early adulthood. So yeah, so I was sort of sort of framing it in that light. What that indicates is that you do need to maintain that sort of healthy balance between omega three and Omega six throughout the entire lifespan, to make sure that you know any sort of psychopathology is held in check in that in that respect, anyways,

Nick Jikomesso you expose pregnant rodents to THC, it throws off the Omega three six balance, and then the offspring end up having effects down the road. Can you unpack that a little bit more for us? What was the direction of the what's the normal balance at baseline between the Omega threes and sixes? Is it roughly one to one? And then in which direction did the THC push things

Steven Lavioletteideally? I mean, it sort of depends on the species we're talking about, and rats generally want to have a bit more omega three than omega six. Okay, and what this did the opposite. So this up the levels in most of the brain areas we look at. Up the levels of omega six, decrease the levels of Omega three

Nick Jikomeswithin the and, I'm sorry, within the brain,

Steven Laviolettewithin the brain. Yes. So we're, we've actually developed an imaging system to look at these fatty acids in the brain. So we can actually visualize the levels of the and quantify the levels of the fatty acids, not just omega six and Omega three, but all of their sort of downstream signaling pathways as well. And so what we were able to show was that, ultimately, you know. Know, we see this disbalance between them, and we see an up regulation of omega six, down regulation of Omega three. And we, we have, have more recently, been able to show that a dietary intervention with omega three fatty acids was able to prevent a lot of those negative impacts. That paper is coming out in a couple of weeks, and so, yeah, so that's really been a focus recently, and that was, of course, a dietary intervention that we gave the pregnant rats while they were being exposed to the THC, and we were able to block a lot of those negative impacts that that was protective all the way into early adulthood.

Nick JikomesI see so it sounds like sort of the the two stories that that have emerged or are emerging are, if you give a pregnant rodent, THC, it throws off the Omega three six balance. It skews it towards Omega sixes. This has long, lasting consequences, negative brain effects, basically, for the offspring down the road. But it sounds like what you're saying is the new story coming out is that if you if you do that, but then you also maybe supplement with omega threes, you can mitigate that effect,

Steven Lavioletteexactly, yeah. So that's the paper that's coming out. And yeah, it was a specialized diet that we had prepared, and it was a high omega three diet. And what? Yeah, and basically what we ripped it was prevent a lot of those negative impacts of THC, you know, there's sort of this misperception that that cannabis during pregnancy is safer than other drugs that other people, that you know, that people may may use to mitigate some of the negative impacts, some of the negative symptoms of pregnancy. But you know, the research that is emerging is showing that they can have profound, profound effects on those pathways. We don't know exactly why this is happening, and that's important to keep in mind, because it's such a complicated biosynthetic pathway, we think that there's probably, you know, some sort of competition going on if you're flooding the brain with these extrinsic cannabinoids that might be competing with the endocannabinoid system, but anandamide and two ag for example, and that's throwing off the normal regulatory pathway and ultimately throwing off skew the balance between omega six and Omega three, and importantly, they the these disturbances were in brain areas that are linked to very serious mental health problems, like the prefrontal cortex, the hippocampus, the striatum, and they're linked to all sorts of risk factors for various problems in later

Nick Jikomeslife. Yeah, yeah. One thing I want to ask you, just as kind of a connoisseur of this area myself, is a bit more detail here about something that I've had Margaret Margaret McCarthy on the podcast before, and she does really cool work, in my opinion, that has to do with the effects of cannabinoids on development, and part of her world involves that, the fact that these things often have sex dependent effects. Did you guys do these studies in male versus female mice, or see anything interesting

Steven Laviolettethat we did? Yeah, I'm glad you asked that we saw massive sex differences, really? Yeah, it was quite remarkable, actually, and even the brain areas that were impacted were different. So I'm hopefully I'm getting this right, but essentially, we were primarily focused on the prefrontal cortex and the hippocampus, which are obviously very important for disorders like mood anxiety disorder, schizophrenia, cognitive problems, whatnot. And what we found was that the impacts on these fatty acid pathways were different in the males and the females. The males had more more profound deficits in the frontal cortex. The females had more profound problems in the hippocampus, and that was reflected in the behavioral symptoms as well. And we again, we don't know exactly why that is because obviously the developing male and female brain are going to be exposed to different hormone levels and whatnot. We we expect is probably something to do with the fetal milieu. But we also work with our collaborators at West at the Western University, Dan Hardy's lab, and he's looking at the way we sort of conduct the research is that Dan Hardy's lab looks at the downstream physiological effects, like on the liver and on the placenta. We published a paper a couple years ago where we showed that the prenatal THC exposure disturbs the transfer of fatty acids, sorry, the vascularization of an area of the placenta called the Labyrinth Zone. And the Labyrinth Zone in the placenta is necessary for sort of that nutrient exchange between the mother in the developing fetus, yeah, so we think it's starting in the placenta and but ultimately, the impacts on males and females is profoundly different, and this persisted all the way into early adulthood. So depending on whether we're talking about a male or female fetus, there's going to be some very different effects, and that has implications. Patients also for intervention strategies, because obviously the frontal cortex and the hippocampus are very different. They subserve very different functions in the brain and are associated with different mental health disorders. So that's sort of the next step in our in the evolution of our research. We're trying to figure out how these intervention strategies, like, for example, a dietary intervention strategy, can that differentially impact the male versus female development? It's

Nick Jikomesreally important question. So you saw, you saw big effects from teaching exposure in pregnant females on their offspring, whether it was males or females, but the effects were just different in each sense,

Steven Lavioletteabsolutely. Yeah, yeah, well, yeah, even we were surprised by that. We were we expected some differences, but nothing that profound, so we were

Nick Jikomesokay. So some of these things can, can be affected by dietary interventions. It sounds like, you know, and we know, I think that THC, so THC is a CB one receptor agonist, and CB one receptors are located all over the place, not just in the brain. I believe they do have direct vascular effects. So that would kind of start to make sense of why you would see some kind of placental exchange phenomenon happening. Yeah,

Steven Lavioletteexactly. Yeah, yeah. I mean, it's a ubiquitous system throughout the entire body, so we sort of, I'm obviously biased towards the brain? But of course, you know, there's a whole sort of peripheral physiology associated with the cannabinoid system as

Nick Jikomeswell. Yeah. And as you mentioned, sort of the biochemistry and the complexity here is really immense, especially when you're talking about these lipid synthesis and exchange pathways and all this stuff. So it can be hard to pinpoint exactly what's going on here, but for me, when I sort of try and distill a lot of this complexity down into something like a general principle, you know, we know that the Omega threes and six is knee the system is evolved or set up in a way that, again, they can't interconvert. They're competing for access to the same enzymes. The the balance of them is very important. And so no matter what the details in the minutia here are for how THC is doing these things. It is somehow throwing off the balance of lipids so that it's outside the normal range of what development is sort of expecting to happen exactly. That's right, interesting. And so one of the things I want to talk about, too, is these things called fatty acid binding proteins. So as you mentioned in the beginning, fats are very important. They're not just structural components. They're used to signaling molecules in the brain. But there's this sort of challenge that our biology has. Is okay, we're an aqueous sack of stuff. We're very watery. So how do we move around fatty things? And one of the ways that fats get moved around is there's special proteins that kind of shuttle them into and or out of cells. So what can you tell us in basic terms about these fatty acid binding proteins and how they work on a high

Steven Laviolettelevel? Yeah, it's a fascinating system, and it's something that we've only you know. The past couple of years, we've sort of been getting into this, primarily because what's remarkable about them is that it's a system that, if you pharmacologically manipulate it, you can bypass the traditional cannabinoid receptor system. And the way they work is that they essentially chaperone or piggyback these endocannabinoids in the aqueous environment and bring them to their degradation sites. And in this case, we're talking let's take anandamide, for example. Anandamide levels need to be tightly regulated, just like any other molecule in the brain, and the way that's done primarily is through fatty acid amine hydrolase, or FAU, F, A, A, h, which is becoming increasingly well known as a modulator of the endocannabinoid system. So essentially, what the fab P proteins do is they chaperone the anandamide to its degradation site and allow it to be degraded, and hence control its availability. We've identified 10 of them so far, and they serve, again, a wide variety of different functions, not just in the brain, but the body as well as would be expected, but in the brain, it's primarily fab p3 fab p5 and fab p7 that are the best understood. There may be more down the road, but those are the ones that we prime. We've identified recently, we've been working with a fab p5 inhibitor, and what we were able to show based on what we what we know about the role of FAB B fives is that if you pharmacologically inhibit fab p5 you can, you can cause anti anxiety and antidepressant like effects in various brain areas. And the hypothesis is that that's because we're increasing levels of anandamide in the brain. Because if you're taking away that system that shuffles it to its degradation site, yeah, you're going to increase it. And there's, there's a wide variety of pre clinical studies using mutant, mutant mouse models, where they and we talked about this in the review paper, where they knock out these very. Various proteins, whether it be fat p3 fat p5 or fat p7 and almost sort of the universal outcome is that you see these elevated levels of anandamide, and that's also associated with anxiolytic effects, or anti anxiety effects. And our lab is also shown is it's it helps to buffer against the effects of chronic stress, and it has acute anti anxiety effects. And what's really interesting about the system, and the reason we started getting into this the signaling system, is because it can bypass the it's not directly activating the CB one or CB two receptors. Yeah, it's an indirect way of modulating them, because obviously, if you take THC, for example, or cannabis, what have you, you're activating CB one, and that's associated with a host of side effects that you don't necessarily want. And of course, some people actually experience acute paranoia and anxiety if they activate the CB one receptor system. So it's not really an ideal target for treating anxiety, even though some people do get, you know, antidepressant and anti anxiety effects. Other people, it depends, sort of a dose dependent thing, right? So depending on your sensitivity to it, you can actually have the opposite effect. So we were, we were interested primarily in using this. It was a proprietary compound we used. We work in collaboration with a company called artello biosciences, and they're based in San Diego, and they've developed these proprietary fab P inhibitors, and so they, you know, ultimately, we wanted to test them in terms of their anxiolytic effects, and we published a couple papers already. We talked about them in the review review paper. There's a few more papers on the way. And we're, we're quite impressed with their anxiolytic and antidepressant properties. And what's, what's really great about them is that, at least in our preclinical models, they don't seem to have any addictive liability. So they don't, they don't seem to modulate, for example, the dopamine system. Most drugs of abuse will activate dopamine. This, these, these compounds don't seem to activate dopamine. They don't seem to produce any negative cognitive effects. So based on, you know, our preliminary pre clinical work, they seem to be a very safe sort of alternative to more traditional compound. And more importantly, as I'm sure you're aware, you know about 12 and a half, 13% of the US population uses benzodiazepines in any given year, and of those people, 2% will develop a very strong dependency on these traditional anti anxiety medications, like the benzodiazepines, and it's a very, very devastating addiction associated with very profound withdrawal symptoms and even longer term physiological side effects that you don't want. So again, what we think is that modulating anandamide through this fat P inhibition system can serve as a safer anxiolytic or antidepressant alternative to the more traditional medications that are out there, and also to cannabis.

Nick JikomesYeah, interesting. So, so again, taking anandamide as an example, the brain is using an antibody. It's secreting it to do normal stuff. In the normal course of biology, one of the ways the brain regulates stuff and how much of it is around, and what's happening is, you know, it'll release something like an endocannabinoid or a neurotransmitter or what have you, and then it will tightly regulate how quickly those things are sort of cleaned up and degraded, and that prevents them from, you know, diffusing around, sticking around for too long, doing, you know, it's just a form of regulation. So anandamide gets released, and then it gets degraded, and that's an important part of its regulation. A key piece in this puzzle for how it gets degraded in this manner is that you've got these fatty acid binding proteins that are basically grabbing it and shuttling it to

Steven Laviolettewhere it gets chopped up. Exactly, yeah, got it. That's exactly how it works, yeah,

Nick Jikomesand so and so, when you have a fab p5 inhibitor in this case, so instead of a drug that is going to say, bind to a receptor like the CB one receptor and activate it or inhibit it, this is binding to the shuttling protein. And this, you're basically saying this seems to have certain advantages. And the way, the way I'm hearing this is, if you have a drug that binds to a receptor, and let's just use CB one as an example, it might bind to that receptor and activate it. It's going to compete with endogenous ligands. It might cause some desensitization or some tolerance. What have you. There's gonna be all of these effects that are secondary, what we think of as side effects, to the primary effect of it actually engaging the receptor. When you have something like this, fab b5 inhibitor, it's not directly engaging the receptor of anandamide. It's just regulating its degradation, and so you're sort of not upsetting the natural pattern of release of anandamide in this case, yeah.

Steven LavioletteYeah, exactly, yeah, and that, and that's, and we think that's largely the reason why it has a better safety profile, because it's not modulating the cannabis system. What's also interesting mentioned is that most of the effects we've seen in terms of its ability to induce anti anxiety effects or antidepressant effects, it actually seems to be CB two dependent so which, which was also very surprising, because naturally you think CB one is more ubiquitous and CB two, we don't. We don't really understand exactly what CB two. CB two is doing. You know, we know it's linked to like ASTRO glios and that sort of thing, astrocytes and some neuro inflammatory mechanisms, mitochondria regulation, for example. But that was quite interesting. So when, so when we tried to block the effects with a CB one antagonist there, there was no blockade, but the CD two antagonist blocked it. So to sort of step back, what we think is happening, and, you know, this is subject to change, but what we think is happening is that the fat p5 inhibitor is a, you know, blocking that chaperone. So we're getting increased levels of anandamide. So where does the anandamide go? We think it's going to CB two to produce these behavioral effects, these anxiolytic effects. And we that's another piece of the puzzle we still have to, we still have to solve, because CB two is such a mystery. So we're trying to figure out exactly how CB two and or its downstream pathways might be related to actual systems, systems level effects.

Nick JikomesWell, yeah, it sounds like there's an important lesson there, which is, you know, when you I mean, this is, this is more general than the area of biology we're talking about. You can, you can look at many areas of biology and see this type of thing, I think. But you know, when you first start learning about the endocannabinoid system, you often learn, CB one is more abundant in the brain, CB two is more abundant in the periphery. And therefore we start to think, if we get sloppy, CB one means Brain Stuff. CB two is not important in the brain. But what you're saying is CB two is important, even though it's not nearly as ubiquitous in the brain. That doesn't mean it's not doing anything substantial. Because in this case, you found an example where it seems to

Steven Laviolettebe exactly and that, and that was the dogma for decades, right? It was CB one. And the dogma for decades was there were no, no CB two receptors in the brain. They thought it was just and that, you know, that's fair enough. It's only been, you know, a few decades that we've actually even, you know, sort of like characterize the cannabinoid receptor system with the studies that were done back in the way back in the 60s. But having said that, yeah, you're absolutely right. I think it's really critical that we consider both the CB one and the CB two system. Obviously, CB two is doing, Does, does have some functional importance in the brain. But, you know, and the other, of course, how it, how it's impacting other neurotransmitters as well, because as I, as I mentioned at the outset, you know, both CB one and CB two are ultimately sort of modulatory systems, right? So they they help to regulate the release of other neuro chemicals, things like serotonin, dopamine, GABA, glutamate. So how are they modulating those different more traditional neurotransmitter systems, which we which we know are very importantly involved in anxiety and depression and addiction, for

Nick Jikomesexample. And then, you know, what can you tell us more about? So I think you said, you know, there's a bunch of FAB fatty acid binding proteins, you know, maybe 10 of them that have been characterized in mammals. And you know, like many things where there's multiple versions of it, you know, one copy might be strongly expressed, one version might be strongly expressed in the brain, another in the liver, and so on and so forth, these things are going to serve slightly different function in all of these different tissues. I think you said fab b5 is one of the ones that's strongly expressed in the brain. Is that true? And what can you start to tell us about what happens when you start messing with Fab b5 in a normal animal? What goes wrong when it's missing, for example? Yeah,

Steven Laviolettewell, if you knock it out, well, actually, I mean, if you knock out it, those proteins you actually see tend to get anxiolytic effects, so similar to pharmacological modulation, the problem there are these animals do have other abnormalities, though there's some studies have shown that they've got other disturbances, and not just fat b5 but fat b3 and fat b7 as well. But of course, it's sort of apples to oranges, because when we're talking about these mutant animals, they're getting the entire system wiped out from birth, right? So, yeah, there's all these sorts of compensatory systems that kick in to sort of compensate for that loss of that, of that system that and that's one of the sort of the shortcomings of that, that technology and using those knockout technology. So there are definitely some side effects from wiping out the entire system from birth, which you would never see in the natural world in any case. So that's why I think it's probably, from a clinical perspective, is better to take more of a pharmacological approach. And so what we've done in our region. Search of we started out by targeting brain areas that we know are involved in anxiety and depression. So for example, we actually started out doing micro infusions of the fat p5 inhibitor in the prefrontal cortex. Then we follow that up with micro infusions into the amygdala. What we found with the prefrontal cortex was that not only did it produce acute anxiolytic effects in these in these rats, these were adult rats, but it also inhibited the output of the amygdala. So the amygdala and the prefrontal cortex are connected with each other. We've studied that pathway for many years now, and so they can excite each other or inhibit each other. And what we found was that, just as an example, the vapid five inhibitor in the prefrontal cortex could could sort of blunt the output from the amygdala, which, of course, is like one of the primary anxiety centers of the brain. If you have an overactive amygdala, you're much more likely to have, you know, symptoms, anxiety disorders, that sort of thing. So that's just one example of sort of a more targeted way to map out the functions of fat p5 as opposed to just sort of a universal knock at mutation,

Nick Jikomesyeah, yeah. Then you know some of the results that you mentioned earlier. You could mitigate the effects of THC, for example, with a dietary intervention. What do you think more generally about, like, just, what does that say about the the potential potency of making dietary fat changes on brain development generally?

Steven LavioletteYeah, I think, I think it's, it's an under, it's sort of a neglected area, because I, you know, and you know, we're certainly guilty of this as well. I think a lot of sort of neuropharmacology research programs focus mostly on traditional neurochemical pathways and small molecules and drugs. You know, we're ultimately looking at pharmacological manipulation, but what if we can do, you know, just simple dietary interventions, and that that's what we were able to show with the other paper as well. There are some really exciting clinical studies out there, like, There's a very famous clinical study called the Vienna Omega three study. And what they did was they gave, I believe it was, a six week dietary intervention with a high omega three diet, and they gave these to a population of people that were at high risk for converting into full schizophrenia, and they were able to show that just that simple dietary intervention for six weeks was able to strongly decrease that conversion rate into psychosis in these people. So you know. But the data is mixed, right? I mean, there have been, there's some positive findings, some negative findings. I don't think we fully understand why some of these studies have been positive. Some have been negative. We know that there's some evidence that if you combine traditional, for example, schizophrenia medications, with dietary omega threes, for example, you can sometimes, in some cases, enhance the impacts, the clinical impacts, of those chronological interventions. So I think there's a huge opportunity to look at how dietary interventions can modulate, not only sort of the baseline risk factors, but also can it improve the efficacy of some of these drugs that we we use, you know, you know, sort of, you know, ad hoc. Can they improve the efficacy of some of these other compounds that we've been used that we know have negative side effects?

Nick JikomesHow do these fatty acid binding proteins tie into things like the HPA axis and stress hormones, do they have an effect there?

Steven LavioletteI don't know. Off the top of my head, I couldn't answer that too well. We haven't studied that ourselves. I would certainly expect that, given its, you know, anti anxiolytic effects, very strong anxiolytic effects, you're going to ultimately regulate cortisol. It's funny, you ask that, because we're actually starting some studies now where we're going to be measuring going to be measuring cortical, cortical cortisol levels following exposure to fat, p5 inhibitors. But we don't have the data yet, so I will have an answer in a few months. But we I would my hypothesis is that it would definitely decrease levels of cortisol, cortical steroids and cortisol, for example, because they are associated with with high anxiety states. I couldn't tell you what the exact mechanism is, but I that sort of at a broader level. I would, I would expect that to be the case.

Nick JikomesOkay, so fab, p5 fatty acid binding protein five, strongly expressed in the brain. This can grab an antimide, bring it into the cell, where it's then degraded. So more fab b5 would mean faster anandamide degradation and lower anandamide levels, which is going to tend to be higher anxiety. And then if you inhibit, you have, say, a fab b5 inhibitor, then it will shuttle in anandamide. Less it will be degraded more. Slowly, that will tend to elevate an anti mind, and that's going to be correlating with anti anxiety effects

Steven Lavioletteand antidepressant as well. I'd add that as well, because we've also been doing some studies looking at chronic stress and so again, these are preclinical models, of course, but obviously the number one cause of mood and anxiety disorders is stress, and it's usually a long term stress that sort of leads people down that clinical path. And so we've been looking at that as well. And you know, and we do have some promising preliminary evidence that the fat p5 can sort of mitigate the impacts of chronic stress as well. One area that we've been looking at is the hippocampus and neurogenesis. So this is, this is data that we've only presented sort of preliminary, preliminary level about essentially what we've been able to show is that fat p5 inhibition can reduce the reduction in neurogenesis that is associated with chronic stress. So if you're under a lot of stress, your hippocampus stops making new neurons, which is called neurogenesis. But what we've been able to show at the preliminary state is that the fab B inhibition can block that process from occurring and allow the hippocampus to continue to produce new neurons, which is correlated with an antidepressant like effect

Nick JikomesI see, I see so most parts of the brain, most of the time, aren't doing neurogenesis. Aren't making new neurons in an adult mammal, but there's a couple special parts of the brain where that does continue to happen. The hippocampus is one of them. And so these things are having an effect on so chronic stress tends to decrease neurogenesis, you know, basically, anxiety, stress, bad stuff, tends to decrease it. And then you see the opposite effect. In the opposite direction. You're seeing that the decrease in neurogenesis that comes from stress is more mild when you mess with these fatty acid binding proteins.

Steven LavioletteExactly, exactly. Yeah, yeah. Interesting. So that's, that's, again, another mechanism, and there's probably others as well. But of course, we've only, we've we've focused primarily on on the hippocampus, on the prefrontal cortex, but I would imagine there might be similar mechanisms happening where other others as well. But of course, the neurogenesis, as you mentioned, neurogenesis is really in adults, is limited primarily to the hippocampus. Yeah.

Nick JikomesSo you've got multiple fatty acid binding proteins, roughly 10 of them in mammals. Fab p5 is the one we're talking about in the brain. Fat p5 binds to anandamide and shuttles it in. That's what we were just discussing. Coincidentally, I was talking to people on the podcast not too long ago focused on a different area of biology and a different tissue, and they were also focused on fab p5 and long story short, what they discovered is that breast cancer cells actually sort of over Express fab p5 and they shuttle in linoleic acid, which is the most abundant PUFA polyunsaturated fatty acid found in seed oils. And you know, connected to mTOR and drove cancer. And you know, that was a separate story. The question I have for you is, okay, if fab p5 is highly expressed in the brain as well, and it's shuttling in anandamide, I'm guessing, in the brain, it can also grab onto linoleic acid. What can you tell me about these fab p5 proteins, and they're obviously not specific for one fatty acid, are they able to grab a bunch of different ones, and how does that start to play into this?

Steven LavioletteYeah, I mean, it's a huge list. I mean, it's not, yeah, I don't. I wouldn't want to give the impression that we're just talking about an animal. It's involved in other endocannabinoids, signaling molecules as well, and other other fatty acids, including linoleic acid. I we've never looked at that specifically, and I'm not off the top of my head, I'm not aware of any study in the brain, and forgive me if I if I missed the data, but I'm not aware of any sort of similar, comparable mechanism with linoleic acid in the brain. But that's very interesting. What you mentioned about breast cancer, I know that there are the the our industry partners we're working with are also running some clinical trials on cancer as well. I unfortunately, I'm not. I don't know too many of the details of those studies, because we're focused on the mood and anxiety side of the story. But there are some promising findings in the cancer sphere as well, and that's probably related to similar mechanisms, but,

Nick Jikomesbut these, these fab p5 proteins in the brain, they're probably, they're probably affecting the shuttling of everything from the endocannabinoids to other dietary fatty acids. And they're, they're grabbing on to many different things,

Steven Lavioletteabsolutely, yeah. And then that's, that's an important thing to keep in mind as well the off target effects. There's always going to be a host of off target effects, and that's part of the reason why we run all these control studies. So for example, if there was a risk that, you know, modulating other fatty acid transport with inhibiting fat p5 What if one of the side effects was to produce dependence? Cognitive deficits. So that's why we run those kinds of control studies, to sort of rule that out as a potential off target side effect. There's a lot more work to do, but I think that's the sort of the given the complexity of not just fat defi but all of the fatty acid binding proteins on what they're responsible for chaperoning in and out of the cell into different degradation sites. It makes the research very challenging, because you have to, you have to account for these off these potential off target side effects as well. And

Nick Jikomeswhen we think about these fab p5 inhibitors, I know that a lot of work has been done over the years trying to, you know, get fat inhibitors to market to, you know, the endocannabinoid system is very important for many things. It ties into anxiety and depression and mood regulation. As we've discussed, thought, inhibitors have, have been the, the object of study for a lot of companies over a lot of years. Can you give us just a sense for like, in terms of, like, endocannabinoid system based drugs for mood regulation, what has worked, what has not worked, and sort of, where does that whole area sit right now? Do are people still excited about fat inhibitors? Are these Fauci Fauci inhibitors like the next thing?

Steven LavioletteWell, you're probably, I'm sure you recall the tragedy that happened with, there was a clinical trial with a fall inhibitor. I believe it was an irreversible fall inhibitor, and I believe there was at least one fatality. This was several years ago. At the top of my head, I don't remember the name of the I think it was in France. This happened, and there was a fatality associated with the use of the fall inhibitor. So I think that did sort of dampen the enthusiasm, because you're right, it was, it was a very 10 years ago. Was a very hot area the use of fo inhibitors. I know there's certainly still interest in it, and there are still companies that are looking at the potential for FAU inhibitors, primarily the reversible FAU inhibitors, as opposed to the irreversible FAU inhibitors, because the irreversible ones appear to have the worst side effects, including things like suicidal ideation, gastrointestinal side effects, that sort of thing. So there are a lot of off target negative impacts associated with FAU inhibitors. But to answer the question, I think there's still some interest in that, probably more interest in the fall inhibitors than fat B, fat P, inhibitory molecules. But yeah, I think it's just sort of something that's going to have to play out with clinical trials. And I'd raise that point also that ultimately we'd like to move ahead with some clinical trials to translate what we've done in the rodent studies into actual populations that are that are suffering with mood and anxiety disorders, to see if there's actually a translational benefit that we can observe with with clinical populations,

Nick Jikomesand so if, if exogenous cannabinoid exposure during Pregnancy can lead to developmental abnormalities that manifest in cognitive and mood problems, and if diet can mitigate that effect, does that also mean that, you know, simply being mindful of diet is sufficient to cause or maybe prevent things like that we might consider mood or cognitive disorders?

Steven LavioletteThat's a great question. I mean, I think that, I think the role of diet is largely ignored in most modern neuroscience. I think Nutritional Neuroscience is a field that really needs to be elevated, because we've certainly, I've talked about a few other studies we've looked at so not just omega threes, we've been looking at antioxidant interventions. We published a few papers with L theanine, for example, and acetylcysteine. These are both antioxidant compounds. You can go into the health food store and just pick your drug store and just pick these up. They're very well tolerated. They have very few side effects. And what we've shown in the preclinical studies is that the antioxidants can block a lot of the negative psychiatric effects of cannabinoid exposure, primarily during most of our studies have focused on adolescent exposure. So as you're no doubt aware, there's a there's a huge clinical correlation between adolescent cannabis use, especially high potency cannabis use and the risk of schizophrenia. So we published a couple papers recently looking at both l theanine and N acetylcysteine interventions to see if they can mitigate the negative impacts of THC, just like I was talking about before, with the Omega threes. And they were very promising. They were able to block a lot of those negative effects. Again, we think this is related to oxidative stress caused by THC, yeah. And that's also linked to neuro inflammation. The two are, like, tightly linked to each other. And so what we're seeing, sort of the story we're seeing emerging, is that, you know, it's probably. Oxidative stress and neuroinflammation that are that is the primary driver of a lot of the pathological risks for extrinsic cannabis exposure, so especially high and, you know, I want to emphasize, we're talking primarily about, like high potency. THC, Now, having said that, there's also been some studies that have come out recently with CBD, which has largely been sort of touted as this miracle cure all for many years now. And there's, there's some, there is some concerning pre clinical evidence suggesting that maternal CBD exposure can lead to some negative, long term side effects as well. So again, that's, we're still that was sort

Nick Jikomesof the work. Yeah. What is that? What is what is known there about CBD? Yeah.

Steven LavioletteSo there's evidence that CBD, maternal CBD exposure, so prenatal th CBD exposure can, can cause a lot of the similar symptoms as THC, so cognitive problems, emotional dysregulation, and they're primarily pre clinical rodent models that have looked at that, but I know that there's a few that have come out. And we also had a paper recently where we looked at THC CBD and the combination of THC and CBD during pre non exposure. And in many cases, the CBD and THC were producing equally negative effects, really sometimes, sometimes the combination would decrease the effects. Sometimes they would synergize the effects. So it's it's a really complicated story that's emerging. But suffice to say, this idea that CBD is this naturally safe and effective option for for dealing with some of the negative symptoms of pregnancy. I think that that that is a myth that is being dispelled by a lot of this research

Nick JikomesI see interesting, and I want to touch on something you mentioned there. So you mentioned that THC can have, can induce oxidative stress and have inflammatory effects. Now some people listening might find that a little confusing, and I want to unpack and emphasize this for people, because I think it's important. There's plenty of other contexts right in which you can go in the literature and say, THC is anti inflammatory. We know that many cannabinoids, endogenous and exogenous are but I think what we need to talk about here is the fact that something can be anti inflammatory and pro inflammatory, because inflammation is not one phenomenon driven by one mechanism. There can be ways that anti inflammatory effects are driven by cannabinoid like THC, for example, and other ways in which it drives, say, oxidative stress. The difference, there could be dose and frequency the difference. There could just be parallel mechanisms that have different effects in different effects in different places. Can you just sort of unpack that for

Steven Laviolettepeople? Yeah, well, as, as you mentioned, I mean, well, one, one of the, one of the complicating factors is the number of routes of administration. So their edibles are becoming more popular. We know the edibles obviously have a different metabolic response in the body, and the amount that gets to the brain is different with smoking it versus eating it. And then there's, there's also very high potency THC extracts like shatter, for example, which that can be almost 90% THC that people are taking. So you know the idea? The general idea, is that if you're taking a product that has roughly equivalent THC to CBD, you're mitigating some of the negative impacts of THC. They're sort of balancing each other out. But we know that, and I'm speaking from the Canadian perspective, where cannabis is, you know, literally on every corner. Now, the most popular cannabis products are contain 25 to 30% THC and like almost no CPD. So we're talking about high potency THC products that are the ones that are the most popular in the marketplace. So we think those are probably the primary culprit for inducing some of these, these sort of oxidative reactions, or neuroinflammatory reactions. But again, we don't fully know, we don't fully know the answer. And you know, there could be things that are happening at the level of the liver, even that that are alter, you know, altering how these effects play out in the brain, even the microbiome that we're doing, we've started doing some microbiome studies as well, and the data is too preliminary to talk about, really, but we do know that edible to edible cannabis exposure can alter the gut microbiome, which is critically linked to, you know, I'm sure you're, You're familiar with the gut brain connection there. So we know that, you know, a lot of neurotransmitter precursors are, you know, come from the gut, and there's this cross talk between the gut and the brain, so I think that might have a lot to do with it, and that's, again, going to be wildly different if you're eating it, and so if you're taking edibles, or you're. Smoking. It smoking is going right. It's, you know, largely right up to the brain, right, going right into the bloodstream, whereas edibles take a much longer time, much sort of a slower tonic reaction. So I think that has a lot to do with it, the potency, the route of administration, and, of course, individual differences. So everyone responds a little differently to cannabis. Not everyone has the same reaction. So, you know, genetic predispositions. We know that certain genetic predispositions make you more likely to suffer from psychiatric side effects of cannabis exposure, and we're just sort of unraveling that. Now we're doing, we're doing a lot of RNA sequencing in our lab. So we're looking at how cannabis exposure can alter the transcriptome of the brain, and what sort of transcriptome changes are induced by cannabis exposure. One of the one of the other models we've moved into recently are organoids. So we're taking basically growing mini brains, which I'm which I'm sure you've heard of. So you basically take an IPSC cell from a patient. So we, we have, um, IPSC cells from patients with schizophrenia, and we take that cell and grow it into a mini brain, right? Yeah, so organoid, and it

Nick Jikomestakes themselves from a tissue sample, and it grows into a mini brain that, on the one hand, has a lot of structural similarities to a real brain that's in a person, but because it's in a dish, you can interrogate it more finely and in more detail, exactly.

Steven LavioletteYeah, so it's sort of a nice intermediate step between the rodent work and actual clinical trials, because we're dealing with real human tissue, real human cells. It's not a perfect model by any means, but it can replicate, like cortical structure, for example. And you know this again, this is not published. Data about what we've what we have done so far is looked at different combinations of THC, CBD, THC and CBD in a dish. And again, what we're finding is that there are profound alterations in those fatty acid pathways, DHA, Ara, sorry, arachidonic acid and other other signaling pathways. It alters various neurotransmitter pathways as well, and some preliminary RNA sequencing, and this is very preliminary data, it's showing that it activates a lot of neuroinflammatory pathways, so the story is all falling together, and it's showing that most of the pathological risk factors we think are probably linked to these oxidative reactions and these neuro inflammatory response.

Nick JikomesOkay, so two things I want to emphasize here for people. So one, you mentioned, you know, a few minutes ago, that there's this notion out there that THC and CBD are the opposite. THC gets you high, and CBD is sort of like the safe, tame one. And in some ways that is true. In many ways, THC and CBD do have functionally distinct and almost opposite effects at the level of, say, the CB one receptor and things like this, but, but it's not, it's not that simple. Unfortunately, you mentioned that. You know, there's data now showing that CBD exposure in the womb can cause problems that are directionally similar to those caused by THC. And so it's unfortunately not going to be the case that we can just think of CBD canceling out the effects of THC or vice versa. And then the other thing is, you mentioned that THC can have these inflammatory or oxidative stress inducing effects, and even though it's true that THC can have anti inflammatory effects, it can bind the CB two receptor. It can do those things, you know, the specific way it's ingested, the specific way it's processed, these ultra complex lipid signaling systems that are being tapped into here mean that, you know, it's probably going to cause both lower and higher inflammation and lower and higher oxidative stress in a dose dependent manner, in a form factor dependent manner, in a exposure length dependent manner. And it's unfortunately not biology is not so simple that you can just say something like THC is anti inflammatory period?

Steven LavioletteYeah, absolutely. And the story keeps evolving. And when we sort of first started dissecting out CBD and THC. We were studying them independently, and, you know, we were able to show that they activated, they went through very different neurochemical pathways. So, for example, CBD primarily produces its effects for the five, HT, one a serotonin receptor, at least in our hand. And there's evidence from other labs as well, showing that it modulates serotonin signaling as well, whereas THC primarily seems to cause a dysregulation of dopamine. And then another study, we were able to show that CBD could actually block hyper dopamine induced by chronic amphetamine exposure, which is. A model, which is a preclinical model of schizophrenia. So the story that was emerging was that they were wildly divergent in their effects. CBD was the good guy. THC was the bad guy, you know, very, very simplistic, but now we know when we started combining them, for example, or looking at different doses, then you start seeing these more subtle, you know, it's not so simple. CBD, you know what? You go back to the idea the dose is the poison, right? So, you know, depending on the dose of CBD, we could see different effects. And depending on the combination of CBD and THC, sometimes CBD can mitigate the negative impacts of THC, but sometimes they seem to actually produce worse effects when they're it's almost like CBD is unlocking some of the negative effects of GHC, and we have no idea why. We don't. We don't know exactly what's happening. And I think ultimately it's going to come down to what brain area we're talking about, right? So we've published research showing that, for example, in the hippocampus, CBD can block a lot of the negative impacts of THC and but that's just looking locally in the hippocampus. But if you look at it from a systemic point of view, if you're giving it like systemically through systemic injections or through edibles, where it's impacting the whole body, then the picture gets way more complicated, and that's something people should keep in mind when, when, sort of reading this literature, you know, you have to consider how localized the effect is. Are you looking at a sort of a system wide effect of these compounds, or are you looking at specific effects in the brain, because ultimately, how these different circuits interact with each other is what's going to lead to the risk, or a reduced risk. And it's, it's, it's, you know, it's hopelessly complex, but ultimately, you know, what we have to do as scientists is sort of adopt a reductionist approach and sort of dissect one circuit at a time. But I would say that, you know, our research has been moving more towards sort of the systemic, global approach. So we're doing a lot of edibles. We're doing a lot of we do, we ultimately start want to start moving into vaporized exposure as well, because most people, of course, still inhale cannabis. Edibles are becoming much more popular, but I think, you know, vaping and and traditional lion's share, it's still the lion's share

Nick Jikomesfor sure. Yeah, interesting. So you know, what are, what are two areas that you're actively working on right now that you're particularly excited about, what? What are some of the questions you're asking? Yeah,

Steven Laviolettewell, I mean, we're still we're continuing with the fat p5 story. So as I said, there's a lot of unanswered questions about that. We want to continue our work into the chronic stress effects and see how the fat p5 might mod p5 inhibitors may modulate some of these chronic stress effects. We're doing some some PTSD type of studies as well to look at its potential therapy, therapeutic impacts for pH PTSD type disorders. We're continuing our intervention studies so dietary intervention studies, We're looking now at trying to figure out, and I alluded to this before, how males and females may differ in their sensitivity to these dietary interventions, and when is the best time to do the intervention? Obviously, it doesn't, you know, our initial study looked at and the one that's coming out in a couple of weeks in molecular psychiatry looked at exposure to this dietary intervention at the same time as they were getting the actual THC. But, you know, obviously given misperceptions around the safety of THC, that's probably not a clinically translatable thing. So most symptoms of serious psychiatric disorders start happening around late adolescence to early adulthood. So what we want to do next is try these dietary interventions during, you know, late adolescence early adulthood, to see if we can prevent the emergence of these symptoms. Yeah, sort of one after the damage has already been done, right? So can we still, Can we somehow mitigate the emergence of those symptoms, similar to that study I was talking about before, the Omega three study, the Vienna study. And not only are we looking at the Omega three dietary interventions, but also, you know, the antioxidants as well. So the ones we've looked at so far, l theanine and the civil system, but there's a host of other ones we can look at as well. Yeah. I

Nick Jikomesmean, I love the idea of exploring whether something like dietary intervention, interventions given at a stage of development like late adolescence, could work because, you know, in the real world, for better or for worse, you know, we can't go back in time and erase what happened prenatal, prenatally or Peri. Italy. But if simple interventions can work before some of these sensitive periods of development have closed, and before a lot of these things emerge, like, you know, different forms of psychosis and mood disorders, you know, to the extent that that can be done, that would be a very, very convenient and effective way to, you know, simply, through simple means, potentially dietary means, you know, help, help people,

Steven Lavioletteexactly, yeah, and you know, that goes on the context of, you know, I mean, the North American diets that we have are horrible, right? I mean, there's already existing problems with the type, you know, we we tend to have a high omega six diet, right in North America, especially, which I think is leading to a lot of, you know, the disbalance between omega threes and Omega sixes and neuroinflammation. And, you know, there's, and there's emerging evidence for that as we move forward. But I think we did, we certainly need to have a serious rethink about right, the dietary culture that we've sort of created, uh, especially in North America, and how that might be contributing to this mental health this mental

Nick Jikomeshealth epidemic? Yeah, no. I mean, I love, I love what you said earlier about, you know, Nutritional Neuroscience being, you know, a new field. Obviously, nutritional psychiatry is, is having a bit of a heyday. And, you know, a lot of people out there, you know, rightfully so, I think, are focusing on the the role of metabolism in psychiatry and mental illness. But one of the things that I think is very destructive and irritating about the way that people tend to ordinarily think about diet and development and health is, I don't know, my whole life growing up, people tended to have the attitude of, oh, when you're young, you can kind of eat anything, and your metabolism works, and then it just sort of magically slows down or breaks later. And it's like, no, no, no, no, no. You are in the process of setting yourself up for it to be broken later by not not feeding it properly early on.

Steven LavioletteYeah. Oh, absolutely. That's, that's a great point. I mean, look at, look at the junk that so many kids eat. And I'm looking, you know, read the ingredients of a box of cereal. I mean, it's just mostly sugar and and it's just, it's quite appalling, really. I mean, part of the problem is that that's it's hard enough to get kids to eat anything, as opposed to nutritional stuff. I, you know, I struggle without my life, but I've got a SEVEN and an eight year old, so I know, I know, I appreciate the challenges of getting your kids to eat a healthy diet. But I think that's, that's an excellent point. I think that the problems are probably starting very early. Yeah, in childhood, we're not sort of getting that necessary balance, especially between these, these fatty acid pathways, particularly Omega six, Omega three. And that's something that we really need to pay more attention to. Yeah,

Nick Jikomesyeah. And I, you know, I'm definitely someone who's been harping on the Omega six, the skewed Omega six composition of diet for a while. It's, I mean, any everywhere I look in the literature, whether I'm talking to the cancer people or the brain people like you, when that ratio is skewed, no good seems to come from it. I can't find a clear example where having, you know, 2120 to one, omega, six to three ratio leads to a good outcome.

Steven LavioletteNo, absolutely not. And that's that's consistent across the, you know, the animal world. I think it's not just, not even just humans, but yeah,

Nick Jikomesyeah. Well, is there anything you want to reiterate, or anything else you want to mention to people about the general subjects we touched on today before we sign off. Oh

Steven Lavioletteno. I mean, I think I would just reiterate that. I think that there's a lot of potential for modulating the fat P system. I think it's sort of, sort of on the ground floor right now, but as we move forward with different studies, I think obviously we're unbiased towards mental health and psychiatric models. But as you mentioned before, I think there's going to be a wide range of applications for modulating the fatty acid binding protein system, for cancer, for neurodegenerative disorders, basically anything that might involve some sort of neuroinflammatory pathology associated with it. So I think it's an exciting time to sort of be looking at these pathways.

Nick JikomesAll right. Well, Professor Steve and LaViolette, thank you again for joining me again. People who are interested in this stuff, we talked about related stuff, but different stuff in our first episode, and that was definitely one of my favorite ones from that season. So thank you very much.

Steven LavioletteThanks for having me here. Appreciate it. Foreign

Nick Jikomes: visit mind and matter.substack.com. To find all of my content. Hey, everyone, I want to take just a minute to tell you about a really cool health monitoring device I've been using called lumit. It's a handheld, pocket sized device with a sleek design. The lumen device measures CO two levels in your breath, which allows their technology to determine the extent to which your body is burning fats versus carbohydrates. Lumen helps improve your metabolic flexibility, your body's efficiency in shifting between using fats and carbs for energy. I use this. Device in the morning or before bed or after meals or after workouts to track my metabolism. With just a couple weeks of use, I learned a lot about which foods were causing my body to burn mostly fat, mostly carbs, or both, as well as how long I needed to fast and how hard I needed to exercise to promote fat burning. Being able to track whether your body is burning fat versus carbs will help you figure out how your body responds to your lifestyle and whether or not your weight loss and fitness strategies are actually working. Lumen is great for anyone looking to optimize their health for either weight loss or athletic performance. Their easy to use app allows you to track your results together with what you're eating and how you're exercising, and it syncs with other devices like the Apple Watch click the link in the episode description to learn more and use the code mind matter, M, I n, d, M, A, T, T, E R, to get 10% off your lumen device today. That's on top of the site wide sale they are currently running, and the lumen device is eligible to be paid for with FSA and HSA health accounts. Check out the link in the episode description for more info. Transcribed by https//otter.ai

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Seed Oils, Omega-3s & Lessons From 93 Years of Life | Artemis Simopoulos | 313

    Nov 17, 20261 hr 35 minAudio

    Send us Fan Mail At 93, Artemis Simopoulos explains why oils once used in paint now dominate the food supply, how a high omega-6 intake slows the making of EPA and DHA, and why cholesterol-lowering corn oil did not...

    Credit the people on this episode

  2. Tendons, Collagen, mTOR & Exercise Adaptation | Keith Baar | Episode 312

    Nov 10, 20262 hrAudio

    Send us Fan Mail Keith Baar explains why tendons stop adapting after 10 minutes of loading, why long low-load holds beat fast reps for connective tissue, and how vitamin C, collagen, caffeine and mTOR shape training....

    Credit the people on this episode

  3. GDF15, Morning Sickness & Mitochondrial Stress | Stephen O'Rahilly | Episode 311

    Nov 3, 20261 hr 29 minAudio

    Send us Fan Mail Dr. Stephen O'Rahilly explains GDF15, a stress hormone that makes us feel sick and eat less, and why morning sickness, and its severe form hyperemesis gravidarum (HG), comes from GDF15 made by the...

    Credit the people on this episode

  4. Psilocybin vs. SSRIs for Depression, Emotional Blunting & How Psychedelics Work | Robin Carhart-Harris | 310

    Oct 26, 20261 hr 56 minAudio

    Send us Fan Mail Robin Carhart-Harris explains why his trial of psilocybin therapy vs. the SSRI escitalopram for depression missed one primary measure but favored psilocybin on almost everything else, and why SSRIs can...

    Credit the people on this episode

  5. This Animal Survives 18 Minutes Without Oxygen | Gary Lewin | 309

    Oct 12, 20261 hr 40 minAudio

    Send us Fan Mail Nick talks with Prof. Gary Lewin (Max DelbrĂĽck Center, Berlin) about naked mole-rats, which in lab tests survived 18 minutes in pure nitrogen by shutting down brain activity, keeping the heart beating,...

    Credit the people on this episode